



ADDRESSING THE BURDEN OF PSORIATIC ARTHRITIS: MOVING BEYOND THE JOINT

REFERENCES

1. Aloush V, Ablin JN, Reitblat T. Fibromyalgia in women with ankylosing spondylitis. *Rheumatol Int.* 2007; 27:865-868.
2. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum.* 2005; 52:1227-1236.
3. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis.* 2005;64:1150-1157.
4. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. *J Am Acad Dermatol.* 2013 Apr;68(4):654-662. doi:10.1016/j.jaad.2012.08.015 Epub 2013 Jan 27
5. ASAS handbook. *Ann Rheum Dis.* 2009; 68 (Suppl II) (with permission).
6. Azevedo VF, dos Santos Paiva E, Felipe, LRH, Moreira, RA. Occurrence of fibromyalgia in patients with ankylosing spondylitis. *Rev Bras Rheumatol.* 2010;50(6):646-654.
7. Baier G, Wagner J. PKC inhibitors: potential in T cell-dependent immune diseases. *Curr Opin Cell Biol.* 2009;21:262-267.
8. Belasco J, Wei N. Psoriatic arthritis: What is happening at the joint? *Rheumatol Ther.* 2019;6:305-315.
9. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. *Br J Dermatol.* 2007;157:1249-1251.
10. Braun J, Inman R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. *Ann Rheum Dis.* 2010;69:1264-1268.
11. Brikman S, Furer V, Wollman J, et al. The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: A cross-sectional study. *J Rheum.* 2016; doi:10.3899/jrheum.151491
12. Brikman S, Furer V, Wollman J, et al. The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: A cross-sectional study. *J Rheumatol.* July 2016.
13. Calin A, Porta J, Fries JD, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. *JAMA.* 1977;237:261.
14. Chandran V, Gottlieb A, Cook RJ, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. *Arthritis Rheum.* 2009;61:1235-1242.
15. Chimenti MS, Caso F, Alivernini S, et al. Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. *Autoimmun Rev.* 2019;18:565-575.
16. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Ann Rheum Dis.* 2010;69:48-53.
17. Coates LC, Mumtaz A, Helliwell PS, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. *J Rheum.* 2011 Jul;38(7):1496-1501.
18. Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (Tight Control of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. *BMC Musculoskelet Disord.* 2013 Mar 21;14:101.
19. Coates LC, Helliwell PS. Methotrexate efficacy in early psoriatic arthritis--Open label data from the TICOPA study. EULAR 2015, Rome, #SAT0556.
20. Coates LC, Helliwell PS. Treat to target in psoriatic arthritis--evidence, target, research agenda. *Curr Rheumatol Rep.* 2015;17:517.
21. Coates L, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. *Arthritis Rheumatol.* 2016;68:1060-1071.
22. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. *Arthritis Rheumatol.* 2016;68(5):1060-1071.
23. Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? *Semin Arthritis Rheum.* 2016;46:291-304.
24. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. *Arthritis Rheum.* 2003;48:523-533.

25. D'Agostino MA, Terslev L, Aegerter P, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. *RMD Open*. 2017;3:e000428.
26. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *J Invest Dermatol*. 2010;130:1785-1796.
27. di Minno MN, Peluso R, Iervolini R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2013;65:141-147.
28. Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W. Idiopathic pain disorders--pathways of vulnerability. *Pain*. 2006;123:226-230. Slide courtesy of Roland Staud MD.
29. Deodhar AA, Gottlieb AB, Boehncke W-H, et al. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study. ACR 2016, Washington DC, #4L.
30. Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. *Rheumatology (Oxford)*. 2014;53:346-352.
31. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. *Ann Rheum Dis*. 2015;74:813-817.
32. Egeberg A, Khalid U, Gislason GH, et al. Association of psoriatic disease with uveitis. A Danish nationwide cohort study. *JAMA Dermatol*. 2015;151:1200-1205. doi:10.1001/jamadermatol.2015.1986
33. Elmamoun M, Leung YY, O'Sullivan D, et al. Using acute-phase reactants to inform the development of instruments for the updated psoriatic arthritis core outcome measurement set. *J Rheumatol*. 2019;46:266-273.
34. EULAR Joint Assessment Manual.
35. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. *J Rheumatol Suppl*. 2012;89:24-28.
36. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. *Int J Med Sci*. 2010;7:284-289.
37. Gladman DD, Mease PJ, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase 3, randomized, controlled trials. ACR 2013, San Diego, #816.
38. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. *N Engl J Med*. 2017;377(16):1525-1536.
39. Glatt S et al. EULAR 2016, London, #OP0108.
40. Gossec L, de Witt, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis*. 2014;73:1012-1019.
41. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update. *Ann Rheum Dis*. 2016;75:499-510.
42. Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. *Nat Rev Rheumatol*. 2016;12:743-750.
43. Gossec L, et al. EULAR 2019, Madrid.
44. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. *Arthritis Rheum*. 2002;46:1333-1343.
45. Graceffa D, Maiani E, Sperduti I, Ceralli F, Bobifati C. Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis. *Clin Exp Dermatol*. 2015;40:136-141.
46. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. *Ann Rheum Dis*. 2015;74(6):1045-1050.
47. Helliwell PS, Porter G, Taylor WJ; forThe CASPAR Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. *Ann Rheum Dis*. 2007;66:113-117.
48. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. *Ann Rheum Dis* 2005;64:ii3-ii8.
49. Højgaard P, Ellegaard K, Nielsen SM, et al. Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study. *Arthritis Care Res (Hoboken)*. 2019;71:798-810.
50. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. *J Rheumatol*. 2013; 40:1349-1356.
51. Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: A population-based Study. *Arthritis Care Res (Hoboken)*. 2017;69:51-57.

52. Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. *J Manag Care Spec Pharm*. 2019;25(1):122-132.
53. Kavanaugh A, et al. *Arthritis Rheum*. 2007.
54. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. *Rheumatology*. 2012;51:1368-1377.
55. Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. *Arthritis Res Ther*. 2019;21:17.
56. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – Results of two phase 3 trials. *N Engl J Med*. 2014;371:326-338.
57. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. *Ann Rheum Dis*. 2013;72:1200-1205.
58. de Lima FB, Abalem MF, Ruiz DG, Gomes B, et al. Prevalence of eye disease in Brazilian patients with psoriatic arthritis. *Clinics (Sao Paulo)*. 2012;67:249-253.
59. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. *Ann Rheum Dis*. 2012;71:1273-1277.
60. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. *J Rheumatol*. 2014;41:887-896.
61. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013;382:780-789.
62. Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. *Ann Rheum Dis*. 2009;68:948-953.
63. Mavers M, Ruderman EM, Perlman H. Intracellular signal pathways: potential for therapies. *Curr Rheum Rep*. 2009;11:378-385.
64. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet*. 2000;356:385-390.
65. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum*. 2004;50:2264-2272.
66. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum*. 2004;50:2264.
67. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*. 2005;52:3279.
68. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. *Ann Rheum Dis*. 2005;64:ii49-ii54.
69. Mease P, van der Heijde D. Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? *Int J Adv Rheumatol*. 2006;4:38-48.
70. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). *Arthritis Care Res (Hoboken)*. 2011;63:64-85. doi:10.1002/ACR.20577
71. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. *Ann Rheum Dis*. 2011;70:77-84.
72. Mease PJ, Woolley J, Bitman B, Wang, BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. *J Rheum*. 2011;38:2461-2465.
73. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. *Ann Rheum Dis*. 2011;70 (Suppl 1) 77-84.
74. Mease et al. EULAR 2012.
75. Mease PJ. Biologic Therapy for Psoriatic Arthritis. *Rheum Dis Clin North Am*. 2015;41:723-738.
76. Mease PJ, Okada M, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52 week results from a phase 3 study. ACR 2016, Washington DC. Abstract 959.
77. Mease PJ, Hall S, FitzGerald O, et al. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic dmards: A randomized, placebo-controlled, phase 3 trial. ACR 2016. Abstract 2983.
78. Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. *Curr Opin Rheumatol*. 2017;29:304-310.
79. Mease PJ, van der Heijde D, Landewé RBM, et al. Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: Primary results from a large randomized, controlled, double-blind phase 3 study. 2017 ACR Annual Meeting. November 3-8, 2017, San Diego, CA. Abstract 17L.

80. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomized, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. *Ann Rheum Dis.* 2017;76(1):79-87.
81. Mease PJ, Gottlieb AB, van der Heijde D. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. *Ann Rheum Dis.* 2017;76(9):1550-1558.
82. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. *N Engl J Med.* 2017;377(16):1537-1550. Mease PJ, et al. EULAR 2018, Amsterdam, OP0307
83. Mease PJ, Gladman DD, van Den Bosch F, et al. Filgotinib, an oral, selective janus kinase 1 inhibitor, is effective in psoriatic patients with an inadequate response to conventional disease-modifying anti-rheumatic drugs: Results from a randomized, placebo-controlled, phase 2 study. ACR 2018, Chicago. Abstract 1821.
84. Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. *Lancet.* 2018;392:2367-2377.
85. Mease P. Neurobiology of Pain. Oxford Textbook of Osteoarthritis. 2018.
86. Mease PJ, Chohan S, Garcia Fructuoso FJ, et al. Randomised, double-blind, placebo-controlled, multiple dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis. EULAR 2019, Madrid. Abstract LB0002.
87. Mease PJ, Smolen JS, Behrens F, et al. Ixekizumab may be superior to adalimumab in bDMARD-naïve patients with PsA. EULAR 2019, Madrid. Abstract LB0005.
88. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomized, open-label, blinded-assessor trial. *Ann Rheum Dis.* 2019.
89. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: Primary results From a randomized, controlled phase III trial. *Arthritis Rheumatol.* 2019. 71:1112-1124.
90. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. *Nat Rev Drug Discov.* 2012;11:763-776.
91. Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. *Autoimmun Rev.* 2014;13:496-502.
92. Moltó A, Etcheto A, Gossec L, et al. Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. *Ann Rheum Dis.* 2018;77:533-540.
93. Musculoskeletal Ultrasound in Rheumatology Review. Pg 227, figure 31(a).
94. Nash P, Kirkham B, Okada M, et al. A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s). EULAR 2017, Madrid. Abstract OP0201.
95. Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. *Lancet.* 2017;389(10086):2317-2327.
96. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. *Mol Immunol.* 2007;44:2497-2506.
97. Ogdie A, Schwartzman S, Eder L, et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. *J Rheumatol.* 2014;41:2315-2322.
98. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. *Rheum Dis Clin North Am.* 2015;41:545-568.
99. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. *Curr Opin Rheumatol.* 2015;27:118-126.
100. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis.* 2015;74:326-332.
101. Ogdie A, Eder L. Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. *Int J Clin Rheumatol.* 2015;10:451-459.
102. Ogdie A, Maliha S, Shin D, et al. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. *Rheumatology (Oxford).* 2017;56:907-911.
103. Ogdie A, Grewal SK, Noe MH, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: A population-based study. *J Invest Dermatol.* 2018;138:760-767.
104. Ogdie A, Palmer JL, Greenberg J, et al. Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. *J Rheumatol.* 2019;46:475-482.
105. Orbai AM, de Wit M, Mease P, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. *Ann Rheum Dis.* 2017;76:673-680.

106. Orbai AM, de Wit M, Mease PJ, et al. Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. *J Rheumatol*. 2017;44:1522-1528.
107. Orbai AM, Ogdie A. Patient-reported outcomes in psoriatic arthritis. *Rheum Dis Clin North Am*. 2016;42:265-283.
108. Papp K, et al. Presented at ESDR 2011, Barcelona.
109. Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. *Clin Exp Rheumatol*. 2013;31:612-620.
110. Ritchlin CT, Gottlieb AB, McInnes IB, et al. Spondylarthropathies and psoriatic arthritis -clinical aspects and treatment: psoriatic arthritis. ACR/ARHP 2012, November 10-14, Washington, DC, USA. Abstract 2557.
111. Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? *Nat Rev Immunol*. 2007;7:191-201.
112. Ruderman E, Pope RM. More than just B-cell inhibition. *Arthritis Res Ther*. 2011;13:125.
113. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. *Arthritis Rheum*. 2006;54:569-778.
114. Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. *Rheumatology (Oxford)*. 2013;52:62-67.
115. Salaffi F, De Angelis R, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. *Rheumatol Int*. 2014;34:1103-1110.
116. Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. *RMD Open*. 2017;3(2):e000588.
117. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. *Ann Rheum Dis*. 2006;65:478-481.
118. Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ. Responsiveness of serum C-reactive protein, interleukin-17A, and interleukin-17F levels of ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double-blind, placebo-controlled trials. *Arthritis Rheumatol*. 2019;71:1660-1669.
119. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). *Ann Rheum Dis*. 2009; 68: 784-788.
120. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. *Ann Rheum Dis*. 2009;68(Suppl II):ii1-ii44. doi:10.1136/ard.2008.104018
121. Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guidelines for the treatment of psoriatic arthritis. *Arthritis Rheumatol*. 2019;71(1):5-32.
122. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. *Physiol Rev*. 2004;84:137-167.
123. Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. *Nat Med*. 2015;21:719-729.
124. Van der Heijde D, Okada M, Lee C, et al. Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixezumab over 52 weeks. EULAR 2017, Madrid. Abstract OP0221.
125. Wallis D, Haroon N, Ayeaerst R, Carty A, Inman RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? *J Rheumatol*. 2013. 40:2038-2041.
126. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. *J Clin Rheumatol*. 2006;12:124-128.
127. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res (Hoboken)*. 2010;62: 600-610.
128. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. *Ann Rheum Dis*. 2008;67:955-959.